Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10916705 | 0.82 | MAPT (0.53) | PDE3BPDE3AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL434348 | 0.78 | CYP11B1 (0.51) | PDE3BPDE3AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL10917444 | 0.77 | PDE3B (0.56) | PDE3BPDE3ACYP11B1CYP11B2MAOA | |
| SCHEMBL3378094 | 0.77 | ALDH1A1 (0.51) | PDE3BPDE3AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL10921282 | 0.76 | PDE3B (0.58) | PDE3BPDE3ACYP11B1CYP11B2MAOA | |
| SCHEMBL14815941 | 0.75 | PDE3B (0.54) | PDE3BPDE3AALDH1A1GAAKDM4E | |
| SCHEMBL10918945 | 0.75 | PDE3B (0.59) | PDE3BPDE3AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL10916724 | 0.75 | CYP11B1 (0.51) | PDE3BPDE3AALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL13692913 | 0.75 | CYP11B1 (0.51) | PDE3BPDE3ACYP11B1CYP11B2MAPT | |
| SCHEMBL787497 | 0.75 | CYP11B1 (0.51) | PDE3BPDE3ACYP11B1CYP11B2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988093-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | WAKABAYASHI HIROAKI (JP) | 2002-05-02 | — | — | US | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6288225-B1 | Substituted benzolactam compounds as substance P antagonists | PFIZER INC | 2001-09-11 | — | — | US | disclosed |
| EP-0840732-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180647-B1 | GASTROINTESTINAL DISORDERS; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2001-01-30 | — | — | US | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| EP-0093922-B1 | BENZOXAZIN-2-ONES, THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| US-4518597-A | THROMBOSIS, ARTERIOSCLEROSIS, ANTITUMOR, ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1985-05-21 | — | — | US | disclosed |
| EP-0093922-A2 | Benzoxazin-2-ones, their preparation and therapeutic agents containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | PDE3B 2199/4885PDE3A 2625/4885ALDH1A1 546/4885 |
| US-20020052503-A1 | Substituted benzolactam compounds as substance p antagonists | NPY1R, OPRM1, OPRL1 | PDE3B 486/4885PDE3A 529/4885ALDH1A1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.